Vemurafenib in metastatic melanoma patients with brain metastases: an open-label, single-arm, phase 2, multicentre study.
Identifieur interne : 004058 ( Ncbi/Merge ); précédent : 004057; suivant : 004059Vemurafenib in metastatic melanoma patients with brain metastases: an open-label, single-arm, phase 2, multicentre study.
Auteurs : G A Mcarthur [Australie] ; M. Maio [Italie] ; A. Arance [Espagne] ; P. Nathan [Royaume-Uni] ; C. Blank [Pays-Bas] ; M-F Avril [France] ; C. Garbe ; A. Hauschild ; D. Schadendorf [Allemagne] ; O. Hamid [États-Unis] ; M. Fluck [Allemagne] ; M. Thebeau [États-Unis] ; J. Schachter [Israël] ; R. Kefford [Australie] ; M. Chamberlain [États-Unis] ; M. Makrutzki [Suisse] ; S. Robson [Suisse] ; R. Gonzalez ; K. Margolin [États-Unis]Source :
- Annals of oncology : official journal of the European Society for Medical Oncology [ 1569-8041 ] ; 2017.
Abstract
Vemurafenib has shown activity in patients with BRAFV600 mutated melanoma with brain metastases (BM). This phase 2 study evaluated vemurafenib in patients with/without prior treatment for BM.
DOI: 10.1093/annonc/mdw641
PubMed: 27993793
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000F60
- to stream PubMed, to step Curation: 000F57
- to stream PubMed, to step Checkpoint: 000F57
Links to Exploration step
pubmed:27993793Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Vemurafenib in metastatic melanoma patients with brain metastases: an open-label, single-arm, phase 2, multicentre study.</title><author><name sortKey="Mcarthur, G A" sort="Mcarthur, G A" uniqKey="Mcarthur G" first="G A" last="Mcarthur">G A Mcarthur</name><affiliation wicri:level="4"><nlm:affiliation>Department of Medical Oncology, Peter MacCallum Cancer Centre, East Melbourne and University of Melbourne, Parkville, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Department of Medical Oncology, Peter MacCallum Cancer Centre, East Melbourne and University of Melbourne, Parkville</wicri:regionArea><orgName type="university">Université de Melbourne</orgName><placeName><settlement type="city">Melbourne</settlement><region type="état">Victoria (État)</region></placeName></affiliation></author><author><name sortKey="Maio, M" sort="Maio, M" uniqKey="Maio M" first="M" last="Maio">M. Maio</name><affiliation wicri:level="1"><nlm:affiliation>AOU Senese Policlinico Santa Maria Alle Scotte, Siena, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>AOU Senese Policlinico Santa Maria Alle Scotte, Siena</wicri:regionArea><wicri:noRegion>Siena</wicri:noRegion></affiliation></author><author><name sortKey="Arance, A" sort="Arance, A" uniqKey="Arance A" first="A" last="Arance">A. Arance</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medical Oncology, Hospital Clínic Barcelona, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Department of Medical Oncology, Hospital Clínic Barcelona</wicri:regionArea><wicri:noRegion>Hospital Clínic Barcelona</wicri:noRegion></affiliation></author><author><name sortKey="Nathan, P" sort="Nathan, P" uniqKey="Nathan P" first="P" last="Nathan">P. Nathan</name><affiliation wicri:level="1"><nlm:affiliation>Mount Vernon Hospital, Centre for Cancer Treatment, Northwood, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Mount Vernon Hospital, Centre for Cancer Treatment, Northwood</wicri:regionArea><wicri:noRegion>Northwood</wicri:noRegion></affiliation></author><author><name sortKey="Blank, C" sort="Blank, C" uniqKey="Blank C" first="C" last="Blank">C. Blank</name><affiliation wicri:level="3"><nlm:affiliation>The Netherlands Cancer Institute, Amsterdam, The Netherlands.</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>The Netherlands Cancer Institute, Amsterdam</wicri:regionArea><placeName><settlement type="city">Amsterdam</settlement><region nuts="2" type="province">Hollande-Septentrionale</region></placeName></affiliation></author><author><name sortKey="Avril, M F" sort="Avril, M F" uniqKey="Avril M" first="M-F" last="Avril">M-F Avril</name><affiliation wicri:level="3"><nlm:affiliation>University Paris Descartes, Hospital Cochin, APHP, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>University Paris Descartes, Hospital Cochin, APHP, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Garbe, C" sort="Garbe, C" uniqKey="Garbe C" first="C" last="Garbe">C. Garbe</name><affiliation><nlm:affiliation>Department of Dermatology, University Hospital Tuebingen, Tuebingen.</nlm:affiliation><wicri:noCountry code="subField">Tuebingen</wicri:noCountry></affiliation></author><author><name sortKey="Hauschild, A" sort="Hauschild, A" uniqKey="Hauschild A" first="A" last="Hauschild">A. Hauschild</name><affiliation><nlm:affiliation>Department of Dermatology, University Hospital Schleswig-Holstein (UKSH), Campus Kiel, Kiel.</nlm:affiliation><wicri:noCountry code="subField">Kiel</wicri:noCountry></affiliation></author><author><name sortKey="Schadendorf, D" sort="Schadendorf, D" uniqKey="Schadendorf D" first="D" last="Schadendorf">D. Schadendorf</name><affiliation wicri:level="1"><nlm:affiliation>Department of Dermatology, Comprehensive Cancer Center, University Hospital Essen, Essen, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Dermatology, Comprehensive Cancer Center, University Hospital Essen, Essen</wicri:regionArea><wicri:noRegion>Essen</wicri:noRegion><wicri:noRegion>Essen</wicri:noRegion><wicri:noRegion>Essen</wicri:noRegion></affiliation></author><author><name sortKey="Hamid, O" sort="Hamid, O" uniqKey="Hamid O" first="O" last="Hamid">O. Hamid</name><affiliation wicri:level="3"><nlm:affiliation>Angeles Clinic and Research Institute, Los Angeles, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Angeles Clinic and Research Institute, Los Angeles</wicri:regionArea><placeName><settlement type="city">Los Angeles</settlement><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Fluck, M" sort="Fluck, M" uniqKey="Fluck M" first="M" last="Fluck">M. Fluck</name><affiliation wicri:level="1"><nlm:affiliation>Fachklinik Hornheide, Munster, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Fachklinik Hornheide, Munster</wicri:regionArea><wicri:noRegion>Munster</wicri:noRegion><wicri:noRegion>Munster</wicri:noRegion><wicri:noRegion>Munster</wicri:noRegion></affiliation></author><author><name sortKey="Thebeau, M" sort="Thebeau, M" uniqKey="Thebeau M" first="M" last="Thebeau">M. Thebeau</name><affiliation wicri:level="1"><nlm:affiliation>Moffitt Cancer Center, Tampa, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Moffitt Cancer Center, Tampa</wicri:regionArea><wicri:noRegion>Tampa</wicri:noRegion></affiliation></author><author><name sortKey="Schachter, J" sort="Schachter, J" uniqKey="Schachter J" first="J" last="Schachter">J. Schachter</name><affiliation wicri:level="1"><nlm:affiliation>Chaim Sheba Medical Centre, Oncology Institute, Ramat-Gan, Israel.</nlm:affiliation><country xml:lang="fr">Israël</country><wicri:regionArea>Chaim Sheba Medical Centre, Oncology Institute, Ramat-Gan</wicri:regionArea><wicri:noRegion>Ramat-Gan</wicri:noRegion></affiliation></author><author><name sortKey="Kefford, R" sort="Kefford, R" uniqKey="Kefford R" first="R" last="Kefford">R. Kefford</name><affiliation wicri:level="1"><nlm:affiliation>Crown Princess Cancer Centre Westmead Hospital and Department of Clinical Medicine, Macquarie University, Sydney NSW, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Crown Princess Cancer Centre Westmead Hospital and Department of Clinical Medicine, Macquarie University, Sydney NSW</wicri:regionArea><wicri:noRegion>Sydney NSW</wicri:noRegion></affiliation></author><author><name sortKey="Chamberlain, M" sort="Chamberlain, M" uniqKey="Chamberlain M" first="M" last="Chamberlain">M. Chamberlain</name><affiliation wicri:level="1"><nlm:affiliation>Seattle Cancer Care Alliance, Seattle, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Seattle Cancer Care Alliance, Seattle</wicri:regionArea><wicri:noRegion>Seattle</wicri:noRegion></affiliation></author><author><name sortKey="Makrutzki, M" sort="Makrutzki, M" uniqKey="Makrutzki M" first="M" last="Makrutzki">M. Makrutzki</name><affiliation wicri:level="1"><nlm:affiliation>F. Hoffmann-La Roche Ltd, Basel, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>F. Hoffmann-La Roche Ltd, Basel</wicri:regionArea><wicri:noRegion>Basel</wicri:noRegion></affiliation></author><author><name sortKey="Robson, S" sort="Robson, S" uniqKey="Robson S" first="S" last="Robson">S. Robson</name><affiliation wicri:level="1"><nlm:affiliation>F. Hoffmann-La Roche Ltd, Basel, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>F. Hoffmann-La Roche Ltd, Basel</wicri:regionArea><wicri:noRegion>Basel</wicri:noRegion></affiliation></author><author><name sortKey="Gonzalez, R" sort="Gonzalez, R" uniqKey="Gonzalez R" first="R" last="Gonzalez">R. Gonzalez</name><affiliation><nlm:affiliation>University of Colorado Cancer Center, Aurora.</nlm:affiliation><wicri:noCountry code="subField">Aurora</wicri:noCountry></affiliation></author><author><name sortKey="Margolin, K" sort="Margolin, K" uniqKey="Margolin K" first="K" last="Margolin">K. Margolin</name><affiliation wicri:level="1"><nlm:affiliation>City of Hope, Duarte, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>City of Hope, Duarte</wicri:regionArea><wicri:noRegion>Duarte</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2017">2017</date><idno type="RBID">pubmed:27993793</idno><idno type="pmid">27993793</idno><idno type="doi">10.1093/annonc/mdw641</idno><idno type="wicri:Area/PubMed/Corpus">000F60</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000F60</idno><idno type="wicri:Area/PubMed/Curation">000F57</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000F57</idno><idno type="wicri:Area/PubMed/Checkpoint">000F57</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000F57</idno><idno type="wicri:Area/Ncbi/Merge">004058</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Vemurafenib in metastatic melanoma patients with brain metastases: an open-label, single-arm, phase 2, multicentre study.</title><author><name sortKey="Mcarthur, G A" sort="Mcarthur, G A" uniqKey="Mcarthur G" first="G A" last="Mcarthur">G A Mcarthur</name><affiliation wicri:level="4"><nlm:affiliation>Department of Medical Oncology, Peter MacCallum Cancer Centre, East Melbourne and University of Melbourne, Parkville, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Department of Medical Oncology, Peter MacCallum Cancer Centre, East Melbourne and University of Melbourne, Parkville</wicri:regionArea><orgName type="university">Université de Melbourne</orgName><placeName><settlement type="city">Melbourne</settlement><region type="état">Victoria (État)</region></placeName></affiliation></author><author><name sortKey="Maio, M" sort="Maio, M" uniqKey="Maio M" first="M" last="Maio">M. Maio</name><affiliation wicri:level="1"><nlm:affiliation>AOU Senese Policlinico Santa Maria Alle Scotte, Siena, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>AOU Senese Policlinico Santa Maria Alle Scotte, Siena</wicri:regionArea><wicri:noRegion>Siena</wicri:noRegion></affiliation></author><author><name sortKey="Arance, A" sort="Arance, A" uniqKey="Arance A" first="A" last="Arance">A. Arance</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medical Oncology, Hospital Clínic Barcelona, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Department of Medical Oncology, Hospital Clínic Barcelona</wicri:regionArea><wicri:noRegion>Hospital Clínic Barcelona</wicri:noRegion></affiliation></author><author><name sortKey="Nathan, P" sort="Nathan, P" uniqKey="Nathan P" first="P" last="Nathan">P. Nathan</name><affiliation wicri:level="1"><nlm:affiliation>Mount Vernon Hospital, Centre for Cancer Treatment, Northwood, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Mount Vernon Hospital, Centre for Cancer Treatment, Northwood</wicri:regionArea><wicri:noRegion>Northwood</wicri:noRegion></affiliation></author><author><name sortKey="Blank, C" sort="Blank, C" uniqKey="Blank C" first="C" last="Blank">C. Blank</name><affiliation wicri:level="3"><nlm:affiliation>The Netherlands Cancer Institute, Amsterdam, The Netherlands.</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>The Netherlands Cancer Institute, Amsterdam</wicri:regionArea><placeName><settlement type="city">Amsterdam</settlement><region nuts="2" type="province">Hollande-Septentrionale</region></placeName></affiliation></author><author><name sortKey="Avril, M F" sort="Avril, M F" uniqKey="Avril M" first="M-F" last="Avril">M-F Avril</name><affiliation wicri:level="3"><nlm:affiliation>University Paris Descartes, Hospital Cochin, APHP, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>University Paris Descartes, Hospital Cochin, APHP, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Garbe, C" sort="Garbe, C" uniqKey="Garbe C" first="C" last="Garbe">C. Garbe</name><affiliation><nlm:affiliation>Department of Dermatology, University Hospital Tuebingen, Tuebingen.</nlm:affiliation><wicri:noCountry code="subField">Tuebingen</wicri:noCountry></affiliation></author><author><name sortKey="Hauschild, A" sort="Hauschild, A" uniqKey="Hauschild A" first="A" last="Hauschild">A. Hauschild</name><affiliation><nlm:affiliation>Department of Dermatology, University Hospital Schleswig-Holstein (UKSH), Campus Kiel, Kiel.</nlm:affiliation><wicri:noCountry code="subField">Kiel</wicri:noCountry></affiliation></author><author><name sortKey="Schadendorf, D" sort="Schadendorf, D" uniqKey="Schadendorf D" first="D" last="Schadendorf">D. Schadendorf</name><affiliation wicri:level="1"><nlm:affiliation>Department of Dermatology, Comprehensive Cancer Center, University Hospital Essen, Essen, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Dermatology, Comprehensive Cancer Center, University Hospital Essen, Essen</wicri:regionArea><wicri:noRegion>Essen</wicri:noRegion><wicri:noRegion>Essen</wicri:noRegion><wicri:noRegion>Essen</wicri:noRegion></affiliation></author><author><name sortKey="Hamid, O" sort="Hamid, O" uniqKey="Hamid O" first="O" last="Hamid">O. Hamid</name><affiliation wicri:level="3"><nlm:affiliation>Angeles Clinic and Research Institute, Los Angeles, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Angeles Clinic and Research Institute, Los Angeles</wicri:regionArea><placeName><settlement type="city">Los Angeles</settlement><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Fluck, M" sort="Fluck, M" uniqKey="Fluck M" first="M" last="Fluck">M. Fluck</name><affiliation wicri:level="1"><nlm:affiliation>Fachklinik Hornheide, Munster, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Fachklinik Hornheide, Munster</wicri:regionArea><wicri:noRegion>Munster</wicri:noRegion><wicri:noRegion>Munster</wicri:noRegion><wicri:noRegion>Munster</wicri:noRegion></affiliation></author><author><name sortKey="Thebeau, M" sort="Thebeau, M" uniqKey="Thebeau M" first="M" last="Thebeau">M. Thebeau</name><affiliation wicri:level="1"><nlm:affiliation>Moffitt Cancer Center, Tampa, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Moffitt Cancer Center, Tampa</wicri:regionArea><wicri:noRegion>Tampa</wicri:noRegion></affiliation></author><author><name sortKey="Schachter, J" sort="Schachter, J" uniqKey="Schachter J" first="J" last="Schachter">J. Schachter</name><affiliation wicri:level="1"><nlm:affiliation>Chaim Sheba Medical Centre, Oncology Institute, Ramat-Gan, Israel.</nlm:affiliation><country xml:lang="fr">Israël</country><wicri:regionArea>Chaim Sheba Medical Centre, Oncology Institute, Ramat-Gan</wicri:regionArea><wicri:noRegion>Ramat-Gan</wicri:noRegion></affiliation></author><author><name sortKey="Kefford, R" sort="Kefford, R" uniqKey="Kefford R" first="R" last="Kefford">R. Kefford</name><affiliation wicri:level="1"><nlm:affiliation>Crown Princess Cancer Centre Westmead Hospital and Department of Clinical Medicine, Macquarie University, Sydney NSW, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Crown Princess Cancer Centre Westmead Hospital and Department of Clinical Medicine, Macquarie University, Sydney NSW</wicri:regionArea><wicri:noRegion>Sydney NSW</wicri:noRegion></affiliation></author><author><name sortKey="Chamberlain, M" sort="Chamberlain, M" uniqKey="Chamberlain M" first="M" last="Chamberlain">M. Chamberlain</name><affiliation wicri:level="1"><nlm:affiliation>Seattle Cancer Care Alliance, Seattle, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Seattle Cancer Care Alliance, Seattle</wicri:regionArea><wicri:noRegion>Seattle</wicri:noRegion></affiliation></author><author><name sortKey="Makrutzki, M" sort="Makrutzki, M" uniqKey="Makrutzki M" first="M" last="Makrutzki">M. Makrutzki</name><affiliation wicri:level="1"><nlm:affiliation>F. Hoffmann-La Roche Ltd, Basel, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>F. Hoffmann-La Roche Ltd, Basel</wicri:regionArea><wicri:noRegion>Basel</wicri:noRegion></affiliation></author><author><name sortKey="Robson, S" sort="Robson, S" uniqKey="Robson S" first="S" last="Robson">S. Robson</name><affiliation wicri:level="1"><nlm:affiliation>F. Hoffmann-La Roche Ltd, Basel, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>F. Hoffmann-La Roche Ltd, Basel</wicri:regionArea><wicri:noRegion>Basel</wicri:noRegion></affiliation></author><author><name sortKey="Gonzalez, R" sort="Gonzalez, R" uniqKey="Gonzalez R" first="R" last="Gonzalez">R. Gonzalez</name><affiliation><nlm:affiliation>University of Colorado Cancer Center, Aurora.</nlm:affiliation><wicri:noCountry code="subField">Aurora</wicri:noCountry></affiliation></author><author><name sortKey="Margolin, K" sort="Margolin, K" uniqKey="Margolin K" first="K" last="Margolin">K. Margolin</name><affiliation wicri:level="1"><nlm:affiliation>City of Hope, Duarte, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>City of Hope, Duarte</wicri:regionArea><wicri:noRegion>Duarte</wicri:noRegion></affiliation></author></analytic><series><title level="j">Annals of oncology : official journal of the European Society for Medical Oncology</title><idno type="eISSN">1569-8041</idno><imprint><date when="2017" type="published">2017</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Vemurafenib has shown activity in patients with BRAFV600 mutated melanoma with brain metastases (BM). This phase 2 study evaluated vemurafenib in patients with/without prior treatment for BM.</div></front></TEI><pubmed><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">27993793</PMID><DateCreated><Year>2016</Year><Month>12</Month><Day>20</Day></DateCreated><DateRevised><Year>2017</Year><Month>04</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1569-8041</ISSN><JournalIssue CitedMedium="Internet"><Volume>28</Volume><Issue>3</Issue><PubDate><Year>2017</Year><Month>Mar</Month><Day>01</Day></PubDate></JournalIssue><Title>Annals of oncology : official journal of the European Society for Medical Oncology</Title><ISOAbbreviation>Ann. Oncol.</ISOAbbreviation></Journal><ArticleTitle>Vemurafenib in metastatic melanoma patients with brain metastases: an open-label, single-arm, phase 2, multicentre study.</ArticleTitle><Pagination><MedlinePgn>634-641</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/annonc/mdw641</ELocationID><Abstract><AbstractText Label="Background" NlmCategory="UNASSIGNED">Vemurafenib has shown activity in patients with BRAFV600 mutated melanoma with brain metastases (BM). This phase 2 study evaluated vemurafenib in patients with/without prior treatment for BM.</AbstractText><AbstractText Label="Methods" NlmCategory="UNASSIGNED">Patients with BRAFV600 mutated melanoma with BM were enrolled into cohort 1 (previously untreated BM) and cohort 2 (previously treated BM) and received vemurafenib (960 mg BID) until disease progression (PD) or intolerance. Primary endpoint was best overall response rate (BORR) in the brain in cohort 1 that was evaluated using modified RECIST 1.1 criteria using lesions ≥0.5 cm to assess response.</AbstractText><AbstractText Label="Results" NlmCategory="UNASSIGNED">146 patients were treated (cohort 1 n = 90; cohort 2 n = 56), 62% of whom were male. Median (range) time since diagnosis of BM: 1.0 (0-9) month in cohort 1 and 4.2 (1-68) months in cohort 2. Median duration of treatment was 4.1 months (range 0.3-34.5) in cohort 1 and 4.1 months (range 0.2-27.6) in cohort 2. Intracranial BORR in cohort 1 by an independent review committee (IRC) was 18% (2 CRs, 14 PRs). Extracranial BORR by IRC was 33% in cohort 1 and 23% in cohort 2. Median PFS (brain only, investigator-assessed) was 3.7 months (range 0.03-33.4; IQR 1.9-5.6) in cohort 1 and 4.0 months (range 0.3-27.4; IQR 2.2-7.4) in cohort 2. Median OS was 8.9 months (range 0.6-34.5; IQR 4.9-17.0) in cohort 1 and 9.6 months (range 0.7-34.3; IQR 4.5-18.4) in cohort 2. Adverse events (AEs) were similar in type, grade and frequency to other studies of single-agent vemurafenib. Grade 3/4 AEs occurred in 59 (66%) patients in cohort 1 and 36 (64%) in cohort 2. Overall, 84% of patients died during the study (86% in cohort 1 and 80% in cohort 2), mainly due to disease progression.</AbstractText><AbstractText Label="Conclusions" NlmCategory="UNASSIGNED">The study demonstrates clinically meaningful response rates of melanoma BM to vemurafenib, which was well tolerated and without significant CNS toxicity.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>McArthur</LastName><ForeName>G A</ForeName><Initials>GA</Initials><AffiliationInfo><Affiliation>Department of Medical Oncology, Peter MacCallum Cancer Centre, East Melbourne and University of Melbourne, Parkville, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maio</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>AOU Senese Policlinico Santa Maria Alle Scotte, Siena, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arance</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Medical Oncology, Hospital Clínic Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nathan</LastName><ForeName>P</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Mount Vernon Hospital, Centre for Cancer Treatment, Northwood, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blank</LastName><ForeName>C</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>The Netherlands Cancer Institute, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Avril</LastName><ForeName>M-F</ForeName><Initials>MF</Initials><AffiliationInfo><Affiliation>University Paris Descartes, Hospital Cochin, APHP, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garbe</LastName><ForeName>C</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Dermatology, University Hospital Tuebingen, Tuebingen.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hauschild</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Dermatology, University Hospital Schleswig-Holstein (UKSH), Campus Kiel, Kiel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schadendorf</LastName><ForeName>D</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Dermatology, Comprehensive Cancer Center, University Hospital Essen, Essen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hamid</LastName><ForeName>O</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Angeles Clinic and Research Institute, Los Angeles, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fluck</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Fachklinik Hornheide, Munster, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thebeau</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Moffitt Cancer Center, Tampa, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schachter</LastName><ForeName>J</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Chaim Sheba Medical Centre, Oncology Institute, Ramat-Gan, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kefford</LastName><ForeName>R</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Crown Princess Cancer Centre Westmead Hospital and Department of Clinical Medicine, Macquarie University, Sydney NSW, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chamberlain</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Seattle Cancer Care Alliance, Seattle, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Makrutzki</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>F. Hoffmann-La Roche Ltd, Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Robson</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>F. Hoffmann-La Roche Ltd, Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gonzalez</LastName><ForeName>R</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>University of Colorado Cancer Center, Aurora.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Margolin</LastName><ForeName>K</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>City of Hope, Duarte, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Ann Oncol</MedlineTA><NlmUniqueID>9007735</NlmUniqueID><ISSNLinking>0923-7534</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">BRAFV600 mutated melanoma</Keyword><Keyword MajorTopicYN="N">brain metastases</Keyword><Keyword MajorTopicYN="N">phase 2 study</Keyword><Keyword MajorTopicYN="N">vemurafenib</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>12</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>12</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>12</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27993793</ArticleId><ArticleId IdType="pii">mdw641</ArticleId><ArticleId IdType="doi">10.1093/annonc/mdw641</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Allemagne</li><li>Australie</li><li>Espagne</li><li>France</li><li>Israël</li><li>Italie</li><li>Pays-Bas</li><li>Royaume-Uni</li><li>Suisse</li><li>États-Unis</li></country><region><li>Californie</li><li>Hollande-Septentrionale</li><li>Victoria (État)</li><li>Île-de-France</li></region><settlement><li>Amsterdam</li><li>Los Angeles</li><li>Melbourne</li><li>Paris</li></settlement><orgName><li>Université de Melbourne</li></orgName></list><tree><noCountry><name sortKey="Garbe, C" sort="Garbe, C" uniqKey="Garbe C" first="C" last="Garbe">C. Garbe</name><name sortKey="Gonzalez, R" sort="Gonzalez, R" uniqKey="Gonzalez R" first="R" last="Gonzalez">R. Gonzalez</name><name sortKey="Hauschild, A" sort="Hauschild, A" uniqKey="Hauschild A" first="A" last="Hauschild">A. Hauschild</name></noCountry><country name="Australie"><region name="Victoria (État)"><name sortKey="Mcarthur, G A" sort="Mcarthur, G A" uniqKey="Mcarthur G" first="G A" last="Mcarthur">G A Mcarthur</name></region><name sortKey="Kefford, R" sort="Kefford, R" uniqKey="Kefford R" first="R" last="Kefford">R. Kefford</name></country><country name="Italie"><noRegion><name sortKey="Maio, M" sort="Maio, M" uniqKey="Maio M" first="M" last="Maio">M. Maio</name></noRegion></country><country name="Espagne"><noRegion><name sortKey="Arance, A" sort="Arance, A" uniqKey="Arance A" first="A" last="Arance">A. Arance</name></noRegion></country><country name="Royaume-Uni"><noRegion><name sortKey="Nathan, P" sort="Nathan, P" uniqKey="Nathan P" first="P" last="Nathan">P. Nathan</name></noRegion></country><country name="Pays-Bas"><region name="Hollande-Septentrionale"><name sortKey="Blank, C" sort="Blank, C" uniqKey="Blank C" first="C" last="Blank">C. Blank</name></region></country><country name="France"><region name="Île-de-France"><name sortKey="Avril, M F" sort="Avril, M F" uniqKey="Avril M" first="M-F" last="Avril">M-F Avril</name></region></country><country name="Allemagne"><noRegion><name sortKey="Schadendorf, D" sort="Schadendorf, D" uniqKey="Schadendorf D" first="D" last="Schadendorf">D. Schadendorf</name></noRegion><name sortKey="Fluck, M" sort="Fluck, M" uniqKey="Fluck M" first="M" last="Fluck">M. Fluck</name></country><country name="États-Unis"><region name="Californie"><name sortKey="Hamid, O" sort="Hamid, O" uniqKey="Hamid O" first="O" last="Hamid">O. Hamid</name></region><name sortKey="Chamberlain, M" sort="Chamberlain, M" uniqKey="Chamberlain M" first="M" last="Chamberlain">M. Chamberlain</name><name sortKey="Margolin, K" sort="Margolin, K" uniqKey="Margolin K" first="K" last="Margolin">K. Margolin</name><name sortKey="Thebeau, M" sort="Thebeau, M" uniqKey="Thebeau M" first="M" last="Thebeau">M. Thebeau</name></country><country name="Israël"><noRegion><name sortKey="Schachter, J" sort="Schachter, J" uniqKey="Schachter J" first="J" last="Schachter">J. Schachter</name></noRegion></country><country name="Suisse"><noRegion><name sortKey="Makrutzki, M" sort="Makrutzki, M" uniqKey="Makrutzki M" first="M" last="Makrutzki">M. Makrutzki</name></noRegion><name sortKey="Robson, S" sort="Robson, S" uniqKey="Robson S" first="S" last="Robson">S. Robson</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004058 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 004058 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Ncbi
|étape= Merge
|type= RBID
|clé= pubmed:27993793
|texte= Vemurafenib in metastatic melanoma patients with brain metastases: an open-label, single-arm, phase 2, multicentre study.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:27993793" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |